- Home
- BEAT vs ANL Comparison
BEAT vs ANL Comparison
Compare BEAT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- ANL
- Stock Information
- Founded
- BEAT 2015
- ANL 2004
- Country
- BEAT United States
- ANL Cayman Islands
- Employees
- BEAT N/A
- ANL N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- ANL
- Sector
- BEAT Technology
- ANL
- Exchange
- BEAT Nasdaq
- ANL Nasdaq
- Market Cap
- BEAT 74.1M
- ANL 79.0M
- IPO Year
- BEAT 2021
- ANL 2023
- Fundamental
- Price
- BEAT $2.26
- ANL $2.12
- Analyst Decision
- BEAT Buy
- ANL Strong Buy
- Analyst Count
- BEAT 1
- ANL 2
- Target Price
- BEAT $8.00
- ANL $9.00
- AVG Volume (30 Days)
- BEAT 110.4K
- ANL 9.1K
- Earning Date
- BEAT 03-19-2025
- ANL 02-24-2025
- Dividend Yield
- BEAT N/A
- ANL N/A
- EPS Growth
- BEAT N/A
- ANL N/A
- EPS
- BEAT N/A
- ANL N/A
- Revenue
- BEAT N/A
- ANL $5,000,000.00
- Revenue This Year
- BEAT N/A
- ANL N/A
- Revenue Next Year
- BEAT N/A
- ANL N/A
- P/E Ratio
- BEAT N/A
- ANL N/A
- Revenue Growth
- BEAT N/A
- ANL N/A
- 52 Week Low
- BEAT $1.35
- ANL $1.85
- 52 Week High
- BEAT $3.48
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- BEAT 47.78
- ANL 50.33
- Support Level
- BEAT $2.02
- ANL $2.01
- Resistance Level
- BEAT $2.44
- ANL $2.17
- Average True Range (ATR)
- BEAT 0.14
- ANL 0.08
- MACD
- BEAT 0.04
- ANL 0.02
- Stochastic Oscillator
- BEAT 50.00
- ANL 74.07
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.